Email this article Effects of different treatments on endothelial function in patients with erectile dysfunction and hypogonadism
- Authors: Mazo EB1, Gamidov SI1, Sotnikova EM1, Mazo EB1, Gamidov SI1, Sotnikova EM1
-
Affiliations:
- Issue: Vol 80, No 12 (2008)
- Pages: 59-63
- Section: Editorial
- URL: https://ter-arkhiv.ru/0040-3660/article/view/30257
- ID: 30257
Cite item
Full Text
Abstract
Aim. To study effects of different treatments on erectile and endothelial functions in patients with erectile dysfunction (ED) and age-related hypogonadism (HG).
Material and methods. The study included 66 males with ED who had clinical and laboratory signs of HG. All the patients were examined using questionnaires (international index of erectile function, AMS), blood hormones tests. Endothelial function was assessed with postcompression tests on the cavernous arteries and blood homocystein assay. All the patients were divided into two matched groups. Group 1 (20 males, mean age 54.6 ± 11.5 years) received androgens only, replacement therapy consisted of testosterone undecanoate (Nebido, Shering) 1000 mg each 10-12 weeks intramuscularly, interval between the first and second injection was 6 weeks. Group 2 (46 males, mean age 53.98 ± 10.03 years) was given combined treatment (androgens and PDE 5 inhibitors), wardenafil (Levitra, Buer Shering Pharma) was used in a dose 20 mg. The treatment lasted 6 months.
Results. AMS points decreased in group 1 from 38.3 ± 0.29 to 29.2 ± 0.32 , in group 2 - from 39.02 ± 0.21 to 28.6 ± 0.95, while testosterone rose from 9.86 ± 0.4 to 17.77 ± 0.42 and 9.35 ± 0.25 to 17.21 ± 0.63 nmol, respectively. Homocystein lowering was significantly more manifest in group 2. EF index in group 2 rose from 11.4 ± 0.77 to 25.54 ± 0.25 points versus 11.2 ± 1.01 to 23.95 ± 0.71 points in group 1, improvement of EF in group 2 occurred sooner. Endothelial function by diameter of the cavernous arteries differed after treatment in group 1 and 2 (19.55 ± 2.88 to 39.2 ± 0.84% and 19.51 ± 1.28 to 48.5 ± 1.76, respectively, p < 0.001).
Conclusion. Combined therapy improves blood homocistein, acts faster and stronger on endothelial and erectile functions and can be recommended as first line for ED and HG patients.
Material and methods. The study included 66 males with ED who had clinical and laboratory signs of HG. All the patients were examined using questionnaires (international index of erectile function, AMS), blood hormones tests. Endothelial function was assessed with postcompression tests on the cavernous arteries and blood homocystein assay. All the patients were divided into two matched groups. Group 1 (20 males, mean age 54.6 ± 11.5 years) received androgens only, replacement therapy consisted of testosterone undecanoate (Nebido, Shering) 1000 mg each 10-12 weeks intramuscularly, interval between the first and second injection was 6 weeks. Group 2 (46 males, mean age 53.98 ± 10.03 years) was given combined treatment (androgens and PDE 5 inhibitors), wardenafil (Levitra, Buer Shering Pharma) was used in a dose 20 mg. The treatment lasted 6 months.
Results. AMS points decreased in group 1 from 38.3 ± 0.29 to 29.2 ± 0.32 , in group 2 - from 39.02 ± 0.21 to 28.6 ± 0.95, while testosterone rose from 9.86 ± 0.4 to 17.77 ± 0.42 and 9.35 ± 0.25 to 17.21 ± 0.63 nmol, respectively. Homocystein lowering was significantly more manifest in group 2. EF index in group 2 rose from 11.4 ± 0.77 to 25.54 ± 0.25 points versus 11.2 ± 1.01 to 23.95 ± 0.71 points in group 1, improvement of EF in group 2 occurred sooner. Endothelial function by diameter of the cavernous arteries differed after treatment in group 1 and 2 (19.55 ± 2.88 to 39.2 ± 0.84% and 19.51 ± 1.28 to 48.5 ± 1.76, respectively, p < 0.001).
Conclusion. Combined therapy improves blood homocistein, acts faster and stronger on endothelial and erectile functions and can be recommended as first line for ED and HG patients.
References
- Hatzichristou D., Hatzimouratidis К., Bekas M. et al. Diagnostic steps in the evaluation of patients with erectile dysfunction. J. Urol. (Baltimore) 2002; 168: 615-620.
- Spark R. F., White R., Connolly P. B. Impotence is not always psychogenic. Newer insights into hypothalamic-pituitary-gonadal dysfunction. J. A. M. A. 1980; 243; 750-755.
- Guay A. T., Velasquez E., Perez J. B. Characterization of patients in a medical endocrine-based center for male sexual dysfunction. Endocr. Pract. 1999; 5: 314-321.
- Dhindsa S., Prabhakar S., Sethi M. et al. Frequent occurrence of hypogonadotropic hypogonadism in type 2 diabetes. J. Clin. Endocrinol. 2004; 89: 5462-5468.
- Jockenhovel F. Testosterone therapy - what, when and to whom? Aging Маlе 2004; 7: 319-324.
- Nieschlag E., Behre H. M. et al. Testosteron: Action, deficiency, substitution. Heidelberg: Springer Verlag; 1990. 51-71.
- Hak A. E., Witteman J. C., de Jong F. H. et al. Low levels of endogenous androgens increase the risk of atherosclerosis in elderly men: the Rotterdam study. J. Clin. Endocrinol. 2002; 87: 3632-3639.
- Mills T. M., Reilly C. M., Lewis R. W. Androgens and penile erection: a review. J. Androl. 1996; 17: 633-638.
- Morelli A., Filippi S., Zhang X. H. et al. Peripheral regulatory mechanisms in erection. Int. J. Androl. 2005; 28 (suppl. 2): 23-27.
- Gooren L. J., Saad F. Recent insights into androgen action on the anatomical and physiological substrate of penile erection. Asian J. Androl. 2006; 8: 3-9.
- Celermajer D. S., Sorensen K. E., Georgakopoulos D. et al. Cigarette smoking is associated with dose-related and potentially reversible impairment of endothelium-dependent dilation in healthy young adults. Circulation 1993; 88: 2149-2155.
- Sasaki S., Higashi Y., Nakagawa К. et al. A low-calorie diet improves endothelium-dependent vasodilation in obese patients with essential hypertension. Am. J. Hypertens. 2002; 15: 302-309.
- Lavrencic A., Salobir B. G., Keber I. Physical training improves flow-mediated dilation in patients with the polymetabolic syndrome. Arterioscler. Thromb. Vasc. Biol. 2000; 20: 551-555.
- Aversa A., Isidori A. M., Spera G. et al. Androgenes improve cavernous vasodilation and response to sildenafil in patients with erectile dysfunction. Clin. Endocrinol. (Oxf.) 2003; 58: 632-638.
- Shabsigh R., Kaufman J. M., Steidle C., Padma-Nathan H. Randomized study of testosterone gel as adjunctive therapy to sildenafil in hypogonadal men with erectile dysfunction who do not respond to sildenafil alone. J. Urol. (Baltimore) 2004; 172 (2): 658-663.
- Greenstein A., Mabjeesh N. J., Sofer M. et al. Does sidenafil combined with testosterone gel improve erectile dysfunction in hypogonadal men in whom testosterone supplement therapy alone failed? J. Urol. (Baltimore) 2005; 173: 530-532.
- Feldman H. A., Goldstein I., Hatzichristou D. G. et al. Impotence and its medical and psychosocial correlates: Results of the Massachusetts Male Aging Study. J. Urol. (Baltimore) 1994; 151: 54-61.
- Zitzmann M., Brune M., Nieschlag E. Vascular reactivity in hypogonadal men is reduced by androgen substitution. J. Clin. Endocrinol. 2002; 87: 5030-5037.
- Yassin A. A., Saad F. Improvement of sexual function in men with late-onset hypogonadism treated with testosterone only. J. Sex. Med. 2007; 4 (2): 497-501.
- Mulhall J. P., Valenzuela R., Aviv N., Parker M. Effect of testosterone supplementation on sexual function in hypogonadal men with erectile dysfunction. Urology 2004; 63 (2): 348-352; discus. 352-353.
- Carosa E., Martini P., Brandetti F. et al. Type V phosphodiesterase inhibitor treatments for erectile dysfunction increase testosterone levels. Clin. Endocrinol. (Oxf.) 2004; 61 (3): 382-386.
Supplementary files
